NCT02717858 is a Phase 1 clinical trial of liraglutide in Metabolism and Nutrition Disorder, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT02717858?

NCT02717858 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT02717858?

Interventions in NCT02717858: liraglutide, placebo.

What condition does NCT02717858 study?

NCT02717858 studies Metabolism and Nutrition Disorder, Obesity.

Is NCT02717858 still recruiting?

NCT02717858 is currently completed. Last updated 28 June 2018.

Last reviewed 2018-06-28 · How we verify

NCT02717858

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

Completed Phase 1 Last updated 28 June 2018

What this trial tests

Phase 1 trial testing liraglutide in Metabolism and Nutrition Disorder in 52 participants. Completed in 27 February 2017.

Timeline

16 March 2016

Primary endpoint
27 February 2017

27 February 2017

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	52
Start date	16 March 2016
Primary completion	27 February 2017
Estimated completion	27 February 2017
Sites	1 location across Denmark

Drugs / interventions tested

liraglutide (liraglutide) — full drug profile →
placebo

Conditions studied

Metabolism and Nutrition Disorder — all drugs for Metabolism and Nutrition Disorder →
Obesity — all drugs for Obesity →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Eligibility, any sex, with Metabolism and Nutrition Disorder or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and tolerability of new-generation anti-obesity medications: a narrative review.
Patel DK, Stanford FC. · · 2018 · cited 73× · PMID 29388462 · DOI 10.1080/00325481.2018.1435129
Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.
Nexøe-Larsen CC, Sørensen PH, Hausner H, Agersnap M, et al · · 2018 · cited 39× · PMID 29892986 · DOI 10.1111/dom.13420
57<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes.
· 2021 · cited 11× · PMID 34468792 · DOI 10.1007/s00125-021-05519-y

Verify or expand the search:

Other trials of liraglutide

Trials testing the same drug.

NCT07244003 — Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control · Phase 4 · recruiting
NCT05965908 — Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome · Phase 3 · completed
NCT05681299 — Effects of GH and Lirglutide on AgRP · Phase 4 · recruiting
NCT03292185 — A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec a · Phase 1 · completed
NCT02964247 — LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. · Phase 3 · completed

Other recruiting trials for Metabolism and Nutrition Disorder

Currently open trials in the same condition.

NCT05785221 — Energy Metabolism Profiles Over Weight-loss and Eating Responses · NA · active not recruiting
NCT03669809 — The Biological Rhythm of Human Metabolite · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02717858 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 28 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02717858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing